Use of a biomarker of norepinephrine transporter (NET) inhibition to assess atomoxetine effects during clinically recommended dosing

被引：0
|
作者：
Leibowitz, M
Ereshefsky, L
Lin, Q
Ledent, E
Padich, R
Allen, A
Jhee, S
Michelson, D
Bieck, PR
Lachno, DR
机构：
[1] Calif Clin Trials, Glendale, CA USA
[2] Eli Lilly & Co, Mont St Aignan, France
[3] Eli Lilly & Co, Neurosci Therapeut Area, Indianapolis, IN 46285 USA
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2005年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S594 / S595
页数：2
相关论文
共 2 条
  • [1] Dihydroxyphenylglycol as a Biomarker of Norepinephrine Transporter Inhibition by Atomoxetine Human Model to Assess Central and Peripheral Effects of Dosing
    Bieck, Peter R.
    Leibowitz, Mark
    Lachno, D. Richard
    Ledent, Edouard
    Padich, Robert
    Jhee, Stan
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2016, 36 (06) : 675 - 683
  • [2] Pharmacodynamics of Norepinephrine Reuptake Inhibition: Modeling the Peripheral and Central Effects of Atomoxetine, Duloxetine, and Edivoxetine on the Biomarker 3,4-Dihydroxyphenylglycol in Humans
    Kielbasa, William
    Lobo, Evelyn
    JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 55 (12): : 1422 - 1431
1